Concepts (135)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart-Assist Devices | 3 | 2021 | 158 | 0.940 |
Why?
|
| Bundle-Branch Block | 2 | 2021 | 15 | 0.830 |
Why?
|
| Heart Failure | 4 | 2021 | 968 | 0.810 |
Why?
|
| Cardiomyopathies | 2 | 2022 | 137 | 0.790 |
Why?
|
| Sarcoidosis | 1 | 2022 | 33 | 0.720 |
Why?
|
| Myocarditis | 5 | 2021 | 68 | 0.710 |
Why?
|
| Angiotensin II | 1 | 2021 | 25 | 0.670 |
Why?
|
| Shock | 1 | 2021 | 34 | 0.670 |
Why?
|
| Vasoconstrictor Agents | 1 | 2021 | 71 | 0.650 |
Why?
|
| Heart Conduction System | 1 | 2021 | 50 | 0.650 |
Why?
|
| Myocardial Infarction | 2 | 2019 | 922 | 0.650 |
Why?
|
| Tachycardia, Ventricular | 1 | 2022 | 131 | 0.640 |
Why?
|
| Amyloidosis | 1 | 2021 | 70 | 0.620 |
Why?
|
| Defibrillators, Implantable | 2 | 2022 | 276 | 0.620 |
Why?
|
| Electrocardiography | 2 | 2021 | 556 | 0.560 |
Why?
|
| Heart Diseases | 1 | 2021 | 223 | 0.550 |
Why?
|
| Heart Arrest | 1 | 2019 | 177 | 0.510 |
Why?
|
| Length of Stay | 2 | 2016 | 828 | 0.430 |
Why?
|
| Patient Selection | 2 | 2016 | 484 | 0.410 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2015 | 171 | 0.410 |
Why?
|
| Disease Management | 1 | 2016 | 235 | 0.410 |
Why?
|
| Syncope | 1 | 2014 | 42 | 0.400 |
Why?
|
| Nitroglycerin | 1 | 2013 | 11 | 0.380 |
Why?
|
| Coronary Vasospasm | 1 | 2013 | 11 | 0.380 |
Why?
|
| Reflex | 1 | 2013 | 27 | 0.380 |
Why?
|
| Bradycardia | 1 | 2013 | 33 | 0.370 |
Why?
|
| Vasodilator Agents | 1 | 2013 | 70 | 0.370 |
Why?
|
| Hypotension | 1 | 2013 | 51 | 0.370 |
Why?
|
| Intracranial Hemorrhage, Hypertensive | 1 | 2012 | 2 | 0.370 |
Why?
|
| Coronary Stenosis | 1 | 2013 | 41 | 0.370 |
Why?
|
| Dobutamine | 1 | 2012 | 12 | 0.360 |
Why?
|
| Antihypertensive Agents | 1 | 2014 | 183 | 0.360 |
Why?
|
| Echoencephalography | 1 | 2012 | 14 | 0.360 |
Why?
|
| Coronary Angiography | 1 | 2013 | 212 | 0.350 |
Why?
|
| Hospital Mortality | 2 | 2018 | 881 | 0.340 |
Why?
|
| Arterial Pressure | 2 | 2021 | 30 | 0.340 |
Why?
|
| Blood Pressure | 1 | 2014 | 537 | 0.330 |
Why?
|
| Aortic Valve Stenosis | 1 | 2014 | 190 | 0.330 |
Why?
|
| Pulmonary Artery | 2 | 2021 | 96 | 0.320 |
Why?
|
| Exercise Test | 1 | 2012 | 257 | 0.320 |
Why?
|
| Retrospective Studies | 8 | 2021 | 6957 | 0.310 |
Why?
|
| Aged | 12 | 2021 | 15147 | 0.280 |
Why?
|
| Hypertension | 1 | 2014 | 618 | 0.270 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2019 | 50 | 0.270 |
Why?
|
| Humans | 21 | 2022 | 65845 | 0.260 |
Why?
|
| Male | 14 | 2021 | 31410 | 0.260 |
Why?
|
| Ventricular Function, Left | 2 | 2020 | 284 | 0.250 |
Why?
|
| Middle Aged | 10 | 2021 | 18501 | 0.210 |
Why?
|
| Atrial Function, Left | 2 | 2021 | 32 | 0.200 |
Why?
|
| Risk Assessment | 3 | 2020 | 2116 | 0.200 |
Why?
|
| Death, Sudden | 1 | 2022 | 31 | 0.180 |
Why?
|
| Aged, 80 and over | 5 | 2021 | 5682 | 0.180 |
Why?
|
| Hemodynamic Monitoring | 1 | 2021 | 2 | 0.180 |
Why?
|
| Remote Sensing Technology | 1 | 2021 | 6 | 0.180 |
Why?
|
| Atrial Pressure | 1 | 2021 | 6 | 0.180 |
Why?
|
| Giant Cells | 1 | 2021 | 16 | 0.170 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2022 | 162 | 0.170 |
Why?
|
| Female | 11 | 2021 | 34425 | 0.170 |
Why?
|
| Stroke Volume | 2 | 2020 | 346 | 0.170 |
Why?
|
| Follow-Up Studies | 3 | 2021 | 2500 | 0.160 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 1 | 2021 | 47 | 0.160 |
Why?
|
| Severity of Illness Index | 3 | 2016 | 1569 | 0.160 |
Why?
|
| Registries | 3 | 2020 | 935 | 0.160 |
Why?
|
| Risk Factors | 5 | 2020 | 5475 | 0.150 |
Why?
|
| Equipment Design | 2 | 2021 | 374 | 0.150 |
Why?
|
| Anatomic Variation | 1 | 2018 | 7 | 0.140 |
Why?
|
| Shock, Cardiogenic | 1 | 2019 | 108 | 0.140 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2020 | 183 | 0.140 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2022 | 370 | 0.140 |
Why?
|
| Esophagus | 1 | 2018 | 47 | 0.140 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 1 | 2018 | 12 | 0.140 |
Why?
|
| Sodium | 1 | 2018 | 60 | 0.140 |
Why?
|
| Predictive Value of Tests | 3 | 2021 | 1117 | 0.140 |
Why?
|
| Neoplasms | 2 | 2019 | 1378 | 0.130 |
Why?
|
| Influenza Vaccines | 1 | 2019 | 100 | 0.130 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2018 | 117 | 0.130 |
Why?
|
| Double Outlet Right Ventricle | 1 | 2016 | 4 | 0.120 |
Why?
|
| Echocardiography | 1 | 2020 | 513 | 0.120 |
Why?
|
| Patient Admission | 1 | 2018 | 200 | 0.120 |
Why?
|
| Telemedicine | 1 | 2021 | 379 | 0.120 |
Why?
|
| Influenza, Human | 1 | 2019 | 213 | 0.120 |
Why?
|
| Models, Cardiovascular | 1 | 2016 | 84 | 0.120 |
Why?
|
| Treatment Outcome | 3 | 2016 | 5834 | 0.120 |
Why?
|
| Mitral Valve | 1 | 2016 | 126 | 0.110 |
Why?
|
| Mitral Valve Insufficiency | 1 | 2016 | 98 | 0.110 |
Why?
|
| Hemodynamics | 1 | 2016 | 253 | 0.110 |
Why?
|
| ST Elevation Myocardial Infarction | 1 | 2016 | 96 | 0.110 |
Why?
|
| Decision Support Techniques | 1 | 2016 | 196 | 0.110 |
Why?
|
| Antineoplastic Agents | 1 | 2020 | 645 | 0.110 |
Why?
|
| Medical Records | 1 | 2014 | 140 | 0.100 |
Why?
|
| Hospitalization | 1 | 2021 | 1404 | 0.100 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2016 | 226 | 0.100 |
Why?
|
| Mechanoreceptors | 1 | 2013 | 13 | 0.100 |
Why?
|
| Vagus Nerve | 1 | 2013 | 20 | 0.090 |
Why?
|
| Patient Discharge | 1 | 2016 | 522 | 0.090 |
Why?
|
| Piperazines | 1 | 2012 | 86 | 0.090 |
Why?
|
| Prevalence | 1 | 2014 | 1454 | 0.070 |
Why?
|
| Massachusetts | 1 | 2014 | 2158 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2020 | 859 | 0.060 |
Why?
|
| Algorithms | 2 | 2021 | 1060 | 0.060 |
Why?
|
| Incidence | 2 | 2020 | 1433 | 0.060 |
Why?
|
| Biomarkers | 2 | 2021 | 1503 | 0.050 |
Why?
|
| Diffusion of Innovation | 1 | 2021 | 67 | 0.040 |
Why?
|
| Endocardium | 1 | 2021 | 14 | 0.040 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2021 | 101 | 0.040 |
Why?
|
| Troponin I | 1 | 2021 | 36 | 0.040 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2021 | 60 | 0.040 |
Why?
|
| Cardiovascular Agents | 1 | 2021 | 107 | 0.040 |
Why?
|
| Time Factors | 2 | 2018 | 3779 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2020 | 296 | 0.040 |
Why?
|
| Biopsy | 1 | 2021 | 463 | 0.040 |
Why?
|
| Heart Transplantation | 1 | 2021 | 180 | 0.040 |
Why?
|
| Immunosuppressive Agents | 1 | 2021 | 382 | 0.040 |
Why?
|
| Heart | 1 | 2021 | 298 | 0.040 |
Why?
|
| Furosemide | 1 | 2018 | 19 | 0.030 |
Why?
|
| Urinalysis | 1 | 2018 | 37 | 0.030 |
Why?
|
| Methylprednisolone | 1 | 2018 | 37 | 0.030 |
Why?
|
| Cadaver | 1 | 2018 | 135 | 0.030 |
Why?
|
| Troponin T | 1 | 2018 | 24 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 2018 | 193 | 0.030 |
Why?
|
| Prognosis | 1 | 2021 | 1793 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2021 | 1719 | 0.030 |
Why?
|
| Glucocorticoids | 1 | 2018 | 190 | 0.030 |
Why?
|
| Melanoma | 1 | 2020 | 335 | 0.030 |
Why?
|
| Vaccination | 1 | 2019 | 388 | 0.030 |
Why?
|
| United States | 2 | 2020 | 8189 | 0.030 |
Why?
|
| Survival Rate | 1 | 2018 | 849 | 0.030 |
Why?
|
| Echocardiography, Doppler | 1 | 2016 | 134 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2018 | 1148 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2016 | 593 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2016 | 488 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2016 | 745 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 2020 | 712 | 0.020 |
Why?
|
| Cardiovascular Diseases | 1 | 2020 | 878 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2018 | 3340 | 0.020 |
Why?
|